Lilly Stock: Next Stop — Can Lilly Stock Reach $2,000?
Investors are watching Lilly stock: next stop as the company leverages obesity and diabetes drugs, while facing risin...
Pharmaceuticals
This tag page gathers 4 Pharmaceuticals articles covering stock moves, earnings previews, and dip-buys to help you evaluate pharma equities and manage risk.
19 articles
This Obesity Drug Stock Surges 60% on Phase 3 News
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Teva Stock Highest Level: Why It Could Soar Further
Teva is shifting from a debt-laden generic player to a branded-focused pharma with a stronger balance sheet. This piv...
Global Alpha Dumps 229,000 Shares: Market Move Explained
A major fund sold almost 230k ANIP shares in Q1, triggering volatility in the pharma stock. This article breaks down ...
Here's Shares Agios Pharmaceuticals: 2026 Outlook and Rally
Biotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
Elanco (ELAN) 2026 Earnings: Key Investor Takeaways
As ELAN reports Q1 2026 earnings, investors want clarity on growth, margins, and guidance. This analysis breaks down ...
Should Lilly Stock Before April 10 Be on Your Radar?
As April 10 approaches, investors debate whether Lilly stock is a buy. This guide breaks down catalysts, valuation, a...
Drug Stocks March 2026: Top 3 Picks for Growth and Safety
In March 2026, the drug stock landscape blends steady demand with ongoing innovation. This article highlights three c...
Recall Affects 90,000 Bottles Children's Ibuprofen
Federal regulators are pulling nearly 90,000 bottles of children's ibuprofen from shelves after reports of foreign ma...
Should Avoid Pfizer? Here's the Key Risk to Watch Today
Pfizer has been a market mover, but recent shifts in demand and patent timelines raise concerns. This guide breaks do...
Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
This Next-Gen Obesity Drug: Can It Save Novo Nordisk?
Novo Nordisk faces intense pressure in the fast-growing obesity treatment space. This article dives into whether this...